Welcome to our dedicated page for Viemed Healthcare SEC filings (Ticker: VMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Viemed Healthcare, Inc. filings document the public-company reporting of a British Columbia issuer with Nasdaq-listed common shares and a U.S. home-based healthcare business. Recent Form 8-K reports furnish quarterly and annual financial results, financial supplements, guidance updates, investor presentation materials, and Regulation FD disclosures tied to Viemed's home medical equipment and chronic disease management operations.
The filing record also covers capital and governance matters, including a definitive proxy statement with annual meeting, governance, and executive compensation disclosures; credit agreement amendments involving Viemed subsidiaries and lenders; and common-share repurchase authorizations and completed repurchase activity. These filings describe the company's capital structure, material agreements, board actions, and formal disclosure controls around furnished operating updates.
Viemed Healthcare Chief Financial Officer Fitzgerald Trae reported equity award activity on January 29, 2026. A block of 9,794 restricted stock units converted into the same number of common shares, and 3,265 cash-settled phantom share units were settled into common shares under the company’s plans.
To cover tax obligations from the restricted stock vesting, 2,679 common shares were withheld by Viemed at a per‑share value of $7.48. In connection with the phantom share settlement, 3,265 common shares were delivered to and simultaneously surrendered back to the company for cash. After these transactions, Trae directly owned 105,638 common shares.
Viemed Healthcare, Inc. Chief Operating Officer and director William Todd Zehnder reported equity compensation vesting and related tax share dispositions. On January 29, 2026, 26,842 restricted stock units converted into an equal number of common shares, and 8,948 cash-settled phantom share units vested, each economically equivalent to one common share.
The company withheld 11,368 common shares at $7.48 per share and a further 8,948 common shares at the same price to cover tax obligations tied to these awards. After these transactions, Zehnder directly owned 390,309 common shares of Viemed Healthcare.
Viemed Healthcare Chief Medical Officer reports equity award vesting and related share transactions. Director and Chief Medical Officer William Frazier reported the vesting of 3,401 Restricted Stock Units (each equal to one common share) and 850 cash-settled phantom share units on January 21, 2026. After these transactions, he directly owned 71,682 common shares.
To cover tax obligations from the RSU vesting, 1,169 common shares were withheld by the company at a per‑share value of $7.49, and 850 common shares were simultaneously acquired and disposed of in connection with settlement of phantom share units for cash. Following the derivative activity, he held 6,800 Restricted Stock Units and 1,700 phantom share units, which were originally granted on January 21, 2025 and vest in three equal annual installments.
Viemed Healthcare President Michael Moore reported equity award vesting and related share movements. On January 21, 2026, 34,214 Restricted Stock Units (RSUs) were converted into an equal number of common shares, and 8,554 phantom share units under the company’s Phantom Share Unit Plan vested, each economically equivalent to one common share.
To cover taxes from RSU vesting, 9,358 common shares were withheld by Viemed Healthcare at a per share value of $7.49, and 8,554 common shares related to the phantom share settlement were disposed of to the company at the same value. After these transactions, Moore directly held 169,590 common shares, 68,428 RSUs and 17,107 phantom share units, and also had an indirect interest in 1,722,614 common shares held by Moore Faster LLC.
Viemed Healthcare, Inc. Chief Executive Officer and director Hoyt Casey reported equity compensation activity and related share movements. On January 21, 2026, 49,597 Restricted Stock Units and 12,400 phantom share units vested, each unit representing the economic equivalent of one common share. In connection with the RSU vesting, the company withheld 13,565 common shares at $7.49 per share to satisfy tax obligations, and 12,400 common shares tied to phantom units were delivered back to the company for cash settlement.
After these transactions, Casey directly holds 324,582 common shares, along with 99,194 RSUs and 24,798 phantom share units. He also has an indirect holding of 1,984,943 common shares through Elizabeth Rose Homes LLC.
Viemed Healthcare, Inc. insider William Todd Zehnder, the Chief Operating Officer and a director, reported equity compensation transactions on 01/21/2026. He exercised 117,548 Restricted Stock Units (RSUs), each converting into one common share, and his directly held common shares increased as part of this vesting.
To cover related tax obligations from the RSU vesting, the company withheld 35,075 common shares at a per‑share value of $7.49, based on the market closing price on January 21, 2026. The filing also shows vesting and settlement of 8,554 cash‑settled phantom share units, economically equivalent to common shares, which resulted in both an acquisition and disposition of the same number of common shares for cash.
After these transactions, Zehnder directly owned 374,835 common shares, along with 235,094 RSUs and 17,107 phantom share units that remain outstanding and continue to represent future or cash‑settled economic exposure to Viemed common shares.
Viemed Healthcare Chief Financial Officer Fitzgerald Trae reported equity award activity involving restricted stock units, phantom share units, and common shares on January 21, 2026. A block of 13,317 restricted stock units vested and converted into common shares, with 4,246 of those shares withheld by the company to cover taxes at a per-share value of $7.49, leaving 98,523 common shares directly held after the transactions. In addition, 3,329 cash-settled phantom share units vested under the company’s Phantom Share Unit Plan, which were economically equivalent to common shares and were settled in cash through a matched acquisition and disposition of 3,329 underlying common shares. Following these events, Trae held 26,632 restricted stock units and 6,658 phantom share units, each unit tied to one common share.
Viemed Healthcare Vice President of Sales Cambre Jerome reported equity award activity and related share transactions. On January 21, 2026, 11,719 Restricted Stock Units (RSUs) vested and were settled into an equal number of common shares, consistent with each RSU representing one common share. To cover taxes from this vesting, the issuer withheld 3,827 common shares at a per-share value of $7.49, based on the market closing price for that date.
The filing also shows vesting of 2,930 cash-settled phantom share units granted under Viemed’s Phantom Share Unit Plan, which are economically equivalent to common shares. The settlement is reported as an exchange of phantom shares for the underlying common shares and a simultaneous disposition of those common shares back to the company for cash. After these transactions, Jerome directly beneficially owned 97,824 common shares, as well as 23,436 RSUs and 5,859 phantom share units that remain outstanding.
Viemed Healthcare General Counsel Jeremy Trahan reported multiple equity-related transactions on January 21, 2026. He exercised and vested 14,648 Restricted Stock Units, each converting into one common share, bringing his directly held common shares at one point to 43,440.
To cover taxes from the RSU vesting, the company withheld 4,783 common shares at a per-share value of $7.49, leaving Trahan with 38,657 common shares after that step. He also had 3,662 cash-settled phantom share units vest under the Phantom Share Unit Plan, economically equivalent to common shares, with settlement reported as both acquisition and disposition of the related common shares.
Following these transactions, Trahan held 29,296 Restricted Stock Units and 7,324 phantom share units, both scheduled to vest in equal annual installments through January 21, 2028, aligning a portion of his compensation with Viemed Healthcare’s share performance over time.
Viemed Healthcare CEO Hoyt Casey reported multiple equity transactions. On January 17, 2026, previously granted awards vested, resulting in the acquisition of 40,068 common shares and 10,017 common shares tied to phantom share vesting. To cover tax obligations and settle cash awards, 12,118 shares were withheld by the company and 10,017 shares were disposed of at $7.33 per share.
Following these transactions, Casey directly held 288,550 common shares and also reported indirect beneficial ownership of 1,984,943 common shares held by Elizabeth Rose Homes LLC. On January 19, 2026, he received new grants of 172,155 restricted stock units and 43,039 phantom share units, each representing the value of one common share and scheduled to vest in three equal annual installments beginning one year after the grant dates.